NASDAQ:HURA

TuHURA Biosciences Q2 2025 Earnings Results & Report

TuHURA Biosciences logo
$1.41 +0.01 (+0.71%)
As of 01:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

TuHURA Biosciences missed analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.21 versus the -$0.14 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

TuHURA Biosciences EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.14
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

TuHURA Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TuHURA Biosciences Q2 2025 Earnings FAQ

TuHURA Biosciences (NASDAQ:HURA) reported earnings of -$0.21 per share for Q2 2025, missing the consensus estimate of -$0.14. The report was announced on Thursday, August 14, 2025.

TuHURA Biosciences Earnings Headlines

RIP USD
In 1974, a quiet deal between Henry Kissinger and the Saudis reshaped America's monetary order overnight, with no announcement and no vote in Congress. Decades later, the dollar had lost more than 84% of its purchasing power even as millionaire ranks surged into the millions. Financial reporter Kimi Weintraub sits down to explore a new, largely unnoticed shift in America's monetary system, one tied to executive orders and a reported 13-nation agreement.tc pixel
See More TuHURA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email.

About TuHURA Biosciences

TuHURA Biosciences (NASDAQ:HURA) is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack.

The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.

TuHURA became a publicly traded company following its 2024 merger with Kintara Therapeutics. The company is based in Tampa, Florida, and is led by President and Chief Executive Officer James Bianco.

View TuHURA Biosciences Profile